NEW YORK – Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer (NYSE: PFE) COVID-19 […]
Drugmakers to Hike US Prices on Over 250 Medications Starting January 1 Read More »
On Thursday, Gilead Sciences (NASDAQ: GILD) said it has appointed Sanofi’s (NASDAQ: SNY) Dietmar Berger as its chief medical officer,
Gilead Appoints Sanofi Official Dietmar Berger as Next Chief Medical Officer Read More »
SHANGHAI – Sanofi (NASDAQ: SNY) plans to invest around 1 billion euros ($1.05 billion) to build a new insulin production
Sanofi Announces its Biggest China Investment Deal Amid EU-China Trade Tensions Read More »
Sanofi (NASDAQ: SNY), the French drugmaker, plans to change its policy on how it gives discounts to certain U.S. hospitals
Sanofi to Revise US Hospital Drug Discount Program, WSJ Reports Read More »
On Friday, Sanofi (NASDAQ: SNY), the French drug maker, posted stronger earnings growth than analysts had expected in the third
Sanofi (NASDAQ: SNY) Posts Q3 Profit Beat on Early Start of Vaccine Sales Read More »
LONDON – Buyout fund CD&R’s keenly awaited 16 billion euro ($17.36 billion) deal to take control of Sanofi’s (NASDAQ: SNY)
Analysis: Dealmakers Expect Bigger European Private Equity Buyouts and More of Them Read More »
PARIS – Sanofi (NASDAQ: SNY) agreed on terms to sell a controlling stake in its consumer health unit Opella to
Sanofi Agrees to Sale Terms for Consumer Health Unit, Say French Government Sources Read More »
PARIS – On Monday, Sanofi (NASDAQ: SNY), the French drugmaker, said it had entered exclusive talks to sell a 50%
Sanofi (NASDAQ: SNY) in Exclusive Talks with CD&R to Sell Consumer Health Unit Opella Read More »
PARIS – On Thursday, Sanofi (NASDAQ: SNY), the French drugmaker, said it was “surprised” by a renewed, higher offer for
Sanofi “Surprised” as PAI Partners Raises Bid for Opella Unit Read More »
PARIS – The French government needs guarantees from drugmaker Sanofi (NASDAQ: SNY) that production of its popular Doliprane painkiller will
France Seeks Job Guarantees from Sanofi Over Doliprane Painkiller Production Read More »
Sanofi (NASDAQ: SNY) is closing in on a deal to sell its consumer health unit for about 15 billion euros
Sanofi (NASDAQ: SNY) Nears $16 Billion Sale of Consumer Health Unit to CD&R, Source Says Read More »
GSK (NYSE: GSK), Sanofi (NASDAQ: SNY), and CSL Ltd have secured $72 million from the U.S. government to ramp up
Sanofi, GSK, CSL Secure $72 Million Funding to Expand US Bird Flu Vaccine Supply Read More »
On Friday, Recordati, the Italian pharma group, said it would buy from Sanofi (NASDAQ: SNY) the global rights to a
Recordati and Sanofi Shares Rise Following $825 Million Drug Rights Deal Read More »
Sanofi (NASDAQ: SNY) has received two separate bids from private equity firms for its consumer health unit, which could be
NEW YORK – Sanofi’s (NASDAQ: SNY) chief executive, Paul Hudson, said in an interview on Monday that the company is
Sanofi (NASDAQ: SNY) CEO Believes New Drugs Will Drive Company Growth Read More »
On Friday, the U.S. Food and Drug Administration said it has approved the use of a drug combination along with
FRANKFURT – On Friday, Sanofi (NASDAQ: SNY) said that its multiple sclerosis drug candidate was shown to delay the worsening
Sanofi (NASDAQ: SNY) Reports Key Milestone in Multiple Sclerosis Drug Development Read More »
Sanofi’s (NASDAQ: SNY) most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat
Sanofi’s (NASDAQ: SNY) Mixed Fortunes in MS Drug Trials Has Market Focus on Win Read More »
On Thursday, Sanofi (NASDAQ: SNY) raised its full-year profit outlook after strong demand for blockbuster asthma drug Dupixent and better-than-expected
HYDERABAD – French drugmaker Sanofi (NASDAQ: SNY) plans to invest 400 million euros ($437.24 million) in its global capacity center
Sanofi (NASDAQ: SNY) Eyes Major Expansion in India with $437 Million Investment Read More »
Bpifrance Executive Director Jose Gonzalo said that the public investment bank is considering a potential investment in Sanofi’s (NASDAQ: SNY)
Sanofi (NASDAQ: SNY) Consumer Health Unit Attracts Interest from Bpifrance Read More »
On Wednesday, Sanofi (NASDAQ: SNY) and partner Regeneron (NASDAQ: REGN) won European Union approval for wider use of their Dupixent
Sanofi (NASDAQ: SNY) Win EU Approval for Dupixent in Chronic Lung Disease Read More »
BERLIN – French drugmaker Sanofi (NASDAQ: SNY) is nearing a decision to invest between 1.3 billion and 1.5 billion euros
Sanofi (NASDAQ: SNY) Plans Billion-Euro Investment in German Insulin Production Facility Read More »
Copyright © 2025 abbonews.com
